Effectiveness of Covid-19 Vaccines over a 9-Month Period

New England Journal of Medicine 386, 933-941

DOI: 10.1056/nejmoa2117128

Citation Report

#	Article	IF	CITATIONS
5	Hospitalized patients with breakthrough COVID-19: Clinical features and poor outcome predictors. International Journal of Infectious Diseases, 2022, 118, 89-94.	3.3	15
7	Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave. Cancer Cell, 2022, 40, 343-345.	16.8	32
8	Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia. Vaccines, 2022, 10, 323.	4.4	1
9	Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective. Frontiers in Microbiology, 2022, 13, 828806.	3.5	17
12	The SARS-CoV-2 Entry Inhibition Mechanisms of Serine Protease Inhibitors, OM-85, Heparin and Soluble HS Might Be Linked to HS Attachment Sites. Molecules, 2022, 27, 1947.	3.8	3
15	Vaccination and immunotherapies in neuroimmunological diseases. Nature Reviews Neurology, 2022, 18, 289-306.	10.1	27
18	Strategies and safety considerations of booster vaccination in COVID-19. Bosnian Journal of Basic Medical Sciences, 2022, , .	1.0	5
19	Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. Metabolism Open, 2022, 14, 100180.	2.9	41
21	Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. The Cochrane Library, 2022, 2022, .	2.8	6
23	Reliably Assessing Duration of Protection for Coronavirus Disease 2019 Vaccines. Journal of Infectious Diseases, 2022, 226, 1863-1866.	4.0	2
24	SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't. Journal of Neural Transmission, 2022, 129, 1155-1167.	2.8	19
25	Clinical Pathways When Considering Antimicrobials for the Treatment of Mild-to-Moderate COVID-19. Military Medicine, 2022, , .	0.8	1
26	COVIDâ€19 vaccination hesitancy among people with chronic neurological disorders: A position paper. European Journal of Neurology, 2022, 29, 2163-2172.	3.3	13
27	COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication. Vaccines, 2022, 10, 718.	4.4	9
28	Trends of COVID-19 incidence in Manitoba and public health measures: March 2020 to February 2022. BMC Research Notes, 2022, 15, 162.	1.4	11
29	Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARSâ€CoVâ€2 Omicron BA.1 variant. MedComm, 2022, 3, e143.	7.2	3
30	Unilateral Erosive Arthritis Following Moderna COVID-19 Vaccination. Cureus, 2022, , .	0.5	1
31	The benefits of large scale covid-19 vaccination. BMJ, The, 2022, 377, o867.	6.0	21

#	Article	IF	Citations
32	Being a Public Health Statistician During a Global Pandemic. Statistical Science, 2022, 37, .	2.8	4
33	Cutaneous symptoms of connective tissue diseases after <scp>COVID</scp> ‶9 vaccination: a systematic review. International Journal of Dermatology, 2022, , .	1.0	O
36	Humoral and cellular immune memory to four COVID-19 vaccines. Cell, 2022, 185, 2434-2451.e17.	28.9	289
37	Autoimmune Skin Disease Exacerbations Following COVID-19 Vaccination. Frontiers in Immunology, 0, 13, .	4.8	13
39	Current vaccine strategies against SARS-CoV-2: Promises and challenges. Journal of Allergy and Clinical Immunology, 2022, 150, 17-21.	2.9	7
40	Investigating COVID-19 Vaccine Impact on the Risk of Hospitalisation through the Analysis of National Surveillance Data Collected in Belgium. Viruses, 2022, 14, 1315.	3.3	0
41	The Effectiveness of COVID-19 Vaccines in Preventing Hospitalizations During the Delta Wave: A Patient-Population Study at a Major Referral Center. Cureus, 2022, , .	0.5	0
44	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nature Medicine, 2022, 28, 1715-1722.	30.7	29
45	Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 986-994.	1.9	18
46	COVID-19 differentiated measures for unvaccinated individuals: The need for clear goals and strong justifications. Vaccine, 2022, 40, 5333-5337.	3.8	5
47	Neutrophil Extracellular Traps, Local IL-8 Expression, and Cytotoxic T-Lymphocyte Response in the Lungs of Patients With Fatal COVID-19. Chest, 2022, 162, 1006-1016.	0.8	26
48	Declining COVID-19 morbidity and case fatality in Germany: the pandemic end?. Infection, 2022, 50, 1625-1626.	4.7	5
49	Production and characterization of chimeric SARS-CoV-2 antigens based on the capsid protein of cowpea chlorotic mottle virus. International Journal of Biological Macromolecules, 2022, 213, 1007-1017.	7.5	3
50	Estimated COVID-19 Severe Cases and Deaths Averted in the First Year Of the Vaccination Campaign in Brazil: A Retrospective Observational Study. SSRN Electronic Journal, 0, , .	0.4	0
52	Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines. Vaccines, 2022, 10, 1014.	4.4	4
53	Immunogenicity and efficacy of Ad26. <scp>COV2</scp> .S: An adenoviral vector–based <scp>COVID</scp> â€19 vaccine. Immunological Reviews, 2022, 310, 47-60.	6.0	10
54	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. Journal of Experimental Medicine, 2022, 219, .	8.5	10
55	The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac. Clinical Microbiology and Infection, 2022, 28, 1636-1643.	6.0	3

#	ARTICLE	IF	Citations
58	Rhinovirus and COVID-19 in children: a new order out of chaos?. Jornal De Pediatria, 2022, , .	2.0	0
59	Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. BMJ, The, 0 , 0 , e071249.	6.0	31
60	Estimating COVID-19 Vaccination and Booster Effectiveness Using Electronic Health Records From an Academic Medical Center in Michigan. , 2022, $1,100015.$		1
61	Elevenâ€month longitudinal study of antibodies in SARSâ€CoVâ€2 exposed and naÃ⁻ve primary health care workers upon COVIDâ€19 vaccination. Immunology, 2022, 167, 528-543.	4.4	2
63	Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case–control study among US veterans. BMJ Open, 2022, 12, e063935.	1.9	16
64	COVID-19 vaccine hesitancy among non-refugees and refugees in Kenya. PLOS Global Public Health, 2022, 2, e0000917.	1.6	6
65	SARS-CoV-2 Vaccination Coverage and Factors Associated with Low Uptake in a Cohort of People Living with HIV. Microorganisms, 2022, 10, 1666.	3 . 6	6
66	Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. Journal of Experimental Medicine, 2022, 219, .	8.5	12
67	Influence of Media Framing on Cognition of COVID-19 Vaccine Effectiveness: The Mediating Role of Emotions. American Journal of Health Behavior, 2022, 46, 423-441.	1.4	0
68	Lessons from a large-scale COVID-19 vaccine trial. Journal of Clinical Investigation, 2022, 132, .	8.2	3
69	COVID-19 vaccine had a significant positive impact on patients with SARS-COV-2 during the third (Omicron) wave in Saudi Arabia. Journal of Infection and Public Health, 2022, 15, 1169-1174.	4.1	8
70	Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection. IScience, 2022, 25, 105105.	4.1	11
71	Effectiveness of BNT162b2 and CoronaVac COVID-19 Vaccination Against Asymptomatic and Symptomatic Infection of SARS-CoV-2 Omicron BA.2 in Hong Kong. SSRN Electronic Journal, 0, , .	0.4	3
72	Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort Study. SSRN Electronic Journal, 0, , .	0.4	3
73	Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States. Mathematical Biosciences and Engineering, 2022, 20, 179-212.	1.9	6
74	Breakthrough COVID-19 Infection During the Delta Variant Dominant Period: Individualized Care Based on Vaccination Status Is Needed. Journal of Korean Medical Science, 2022, 37, .	2.5	7
75	Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue. Journal of Occupational and Environmental Medicine, 2022, 64, 788-796.	1.7	0
76	Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection. Clinical Drug Investigation, 2022, 42, 799-806.	2.2	0

#	Article	IF	Citations
77	Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes. JAMA - Journal of the American Medical Association, 2022, 328, 1415.	7.4	76
78	Covid-19 Vaccines — Immunity, Variants, Boosters. New England Journal of Medicine, 2022, 387, 1011-1020.	27.0	266
79	COVID-19 Vaccine Effectiveness during a Prison Outbreak when Omicron was the Dominant Circulating Variantâ€"Zambia, December 2021. American Journal of Tropical Medicine and Hygiene, 2022, 107, 1055-1059.	1.4	3
80	Rate of True-Positive Findings of COVID-19 Typical Appearance at Chest CT per RSNA Consensus Guidelines in an Increasingly Vaccinated Population. Radiology, 2023, 306, .	7.3	7
81	Insights into Controlling the Spread of COVID-19: A Study Inspired by Seven of the Earliest Vaccinated Countries. Journal of Environmental and Public Health, 2022, 2022, 1-14.	0.9	1
82	Durability of Protection Post–Primary COVID-19 Vaccination in the United States. Vaccines, 2022, 10, 1458.	4.4	8
83	COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021–2022. Open Forum Infectious Diseases, 2022, 9, .	0.9	7
84	Evolution of Care and Outcomes Across Surges in Hospitalized Patients with Coronavirus Disease 2019. American Journal of Medicine, 2022, , .	1.5	0
85	Psychotropic drugs interaction with the lipid nanoparticle of COVID-19 mRNA therapeutics. Frontiers in Pharmacology, 0, 13, .	3.5	0
87	Effects of Vaccination and Previous Infection on Omicron Infections in Children. New England Journal of Medicine, 2022, 387, 1141-1143.	27.0	37
88	Extension of Interval-Valued Fermatean Fuzzy TOPSIS for Evaluating and Benchmarking COVID-19 Vaccines. Mathematics, 2022, 10, 3514.	2.2	13
89	Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains. Viruses, 2022, 14, 2016.	3.3	8
90	Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. The Cochrane Library, 2022, 2022, .	2.8	23
91	Shedding of infectious SARS-CoV-2 despite vaccination. PLoS Pathogens, 2022, 18, e1010876.	4.7	36
92	Publications About COVID-19 Research by the BME Community. Annals of Biomedical Engineering, 0, , .	2.5	0
93	Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults. Clinical Infectious Diseases, 2023, 76, 252-262.	5.8	7
94	Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. Journal of Clinical Investigation, 2022, 132, .	8.2	18
96	Examining the Prevailing Negative Sentiments Related to COVID-19 Vaccination: Unsupervised Deep Learning of Twitter Posts over a 16 Month Period. Vaccines, 2022, 10, 1457.	4.4	23

#	Article	IF	Citations
97	Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021. BMC Medicine, 2022, 20, .	5 . 5	28
98	Estimating conditional vaccine effectiveness. European Journal of Epidemiology, 2022, 37, 885-890.	5.7	2
99	Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study. Open Forum Infectious Diseases, 2022, 9, .	0.9	7
101	Overcoming "failures of imaginationâ€â€"rethinking the US covid-19 pandemic response. BMJ, The, 0, , o2397.	6.0	2
102	A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent Vaccine Schedules, COVID-19 Vaccine Side Effects, and Effectiveness Against Omicron and Delta Variants. Cureus, 2022, , .	0.5	10
103	Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study. , 2022, 1, e000104.		12
104	Changes in Social and Clinical Determinants of COVID-19 Outcomes Achieved by the Vaccination Program: A Nationwide Cohort Study. International Journal of Environmental Research and Public Health, 2022, 19, 12746.	2.6	2
105	Predictors of COVID-19 Vaccine Uptake in Teachers: An On-line Survey in Greece. Journal of Community Health, 2023, 48, 59-66.	3.8	3
106	Genomic Transcriptome Benefits and Potential Harms of COVID-19 Vaccines Indicated from Optimized Genomic Biomarkers. Vaccines, 2022, 10, 1774.	4.4	3
107	Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals. IScience, 2022, 25, 105455.	4.1	10
109	Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. JAMA Network Open, 2022, 5, e2236397.	5.9	19
110	Outcomes of COVID-19 in heart failure, LVAD, and heart transplant patients in an advanced heart failure practice. American Heart Journal Plus, 2022, 24, 100223.	0.6	1
111	Combining predictive models with future change scenarios can produce credible forecasts of COVID-19 futures. PLoS ONE, 2022, 17, e0277521.	2.5	3
112	The "vaccine―hubbub: Viral load comparisons of SARSâ€CoVâ€2 Delta and Omicron variants against different vaccine–booster vaccine combinations. Journal of Medical Virology, 2023, 95, .	5.0	0
113	High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. BMC Infectious Diseases, 2022, 22, .	2.9	24
115	Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study. Vaccines, 2022, 10, 1931.	4.4	1
116	Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents: A Systematic Review and Meta-Analysis. Vaccines, 2022, 10, 1880.	4.4	16
117	Public misperceptions of COVID-19 vaccine effectiveness and waning: experimental evidence from Ireland. Public Health, 2023, 214, 81-84.	2.9	3

#	ARTICLE	IF	CITATIONS
118	Estimated COVID-19 severe cases and deaths averted in the first year of the vaccination campaign in Brazil: a retrospective observational study. The Lancet Regional Health Americas, 2023, 17, 100418.	2.6	4
119	Incidence of SARS-CoV-2 infection in hospital workers before and after vaccination programme in East Java, Indonesia – aÂretrospective cohort study. , 2023, 10, 100130.		5
120	Association between job role and coronavirus disease 2019 (COVID-19) among healthcare personnel, lowa, 2021. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.5	0
121	IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	7
122	Drivers of and Barriers to COVID-19 Vaccine Booster Dose Acceptance in Indonesia. Vaccines, 2022, 10, 1981.	4.4	3
123	Current Challenges With the Use of Test-Negative Designs for Modeling COVID-19 Vaccination and Outcomes. American Journal of Epidemiology, 2023, 192, 328-333.	3.4	12
124	Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression. BMC Medicine, 2022, 20, .	5.5	8
125	Impact of Vaccination, Prior Infection, and Therapy on Omicron Infection and Mortality. Journal of Infectious Diseases, 2023, 227, 970-976.	4.0	6
126	Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Lancet Infectious Diseases, The, 2023, 23, 421-434.	9.1	24
127	SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients. Microbiology Spectrum, 2022, 10, .	3.0	3
128	Recent developments in the immunopathology of <scp>COVID</scp> â€19. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 369-388.	5.7	33
129	Effectiveness of COVID-19 Vaccines over 13 Months Covering the Period of the Emergence of the Omicron Variant in the Swedish Population. Vaccines, 2022, 10, 2074.	4.4	3
130	Community risks for SARS-CoV-2 infection among fully vaccinated US adults by rurality: A retrospective cohort study from the National COVID Cohort Collaborative. PLoS ONE, 2023, 18, e0279968.	2.5	2
132	Evaluating Johnson and Johnson COVID-19 Vaccination Outcomes in a Low-Income Hispanic Population. Vaccines, 2023, 11, 148.	4.4	1
133	Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case–control study. PLoS Medicine, 2023, 20, e1004156.	8.4	5
135	COVID-19 Vaccines—All You Want to Know. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 143-172.	2.1	4
136	Heritability of Protein and Metabolite Biomarkers Associated with COVID-19 Severity: A Metabolomics and Proteomics Analysis. Biomolecules, 2023, 13, 46.	4.0	3
137	Racial, ethnic, and socioeconomic disparities in COVID-19 and influenza vaccination in pediatric food allergy, 2022, 4, 172-180.	0.2	0

#	ARTICLE	IF	CITATIONS
138	Vaccinating Children against SARS-CoV-2: A Literature Review and Survey of International Experts to Assess Safety, Efficacy and Perceptions of Vaccine Use in Children. Vaccines, 2023, 11, 78.	4.4	4
140	Effectiveness of Bivalent Boosters against Severe Omicron Infection. New England Journal of Medicine, 2023, 388, 764-766.	27.0	129
141	Towards a Future of Personalized Vaccinology: Study on Individual Variables Influencing the Antibody Response to the COVID-19 Vaccine. Vaccines, 2023, 11, 217.	4.4	3
142	Unsaturated, Trialkyl Ionizable Lipids are Versatile Lipidâ€Nanoparticle Components for Therapeutic and Vaccine Applications. Advanced Materials, 0, , 2209624.	21.0	17
143	Main Manifestations of the Psychological and Behavioural Impacts of the COVID-19 Pandemic on Populations. Advances in Public Policy and Administration, 2022, , 43-64.	0.1	0
144	Covid-19 Vaccine Efficacy: Accuracy Assessment, Comparison, and Caveats. Journal of Data Science, 2024, , 45-55.	0.9	0
145	The effect of mixed vaccination rollout strategy: A modelling study. Infectious Disease Modelling, 2023, 8, 318-340.	1.9	0
146	SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 – June 30, 2021. Vaccine, 2023, 41, 1295-1298.	3.8	0
147	Impact of Vaccination on Cost and Course of Hospitalization Associated with COVID-19 Infection. Antimicrobial Stewardship & Healthcare Epidemiology, 2023, 3, .	0.5	1
148	Mistrust in government and COVID-19 vaccination acceptance in Nigeria: investigating the indirect roles of attitudes towards vaccination. Journal of the Egyptian Public Health Association, The, 2023, 98, .	2.5	2
150	Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data. International Journal of Infectious Diseases, 2023, 129, 188-196.	3.3	10
151	Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respiratory Medicine, the, 2023, 11, 439-452.	10.7	69
152	Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals. PLoS ONE, 2023, 18, e0281689.	2.5	8
153	Persons with HIV Develop Spike-Specific Lymph Node Germinal Center Responses following SARS-CoV-2 Vaccination. Journal of Immunology, 2023, 210, 947-958.	0.8	0
154	Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. Med, 2023, 4, 191-215.e9.	4.4	16
155	Simulating potential outbreaks of Delta and Omicron variants based on contact-tracing data: A modelling study in Fujian Province, China. Infectious Disease Modelling, 2023, 8, 270-281.	1.9	1
156	Reporting rates for <scp>VAERS</scp> death reports following <scp>COVID</scp> â€19 vaccination, December 14, 2020–November 17, 2021. Pharmacoepidemiology and Drug Safety, 0, , .	1.9	0
157	Comparing the control of COVID-19 epidemic before and after the implementation of rapid response program in southeast of Iran. Payesh, 2023, 22, 73-82.	0.2	0

#	ARTICLE	IF	CITATIONS
158	The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: a registry-based study. The Lancet Regional Health Americas, 2023, 20, 100465.	2.6	6
159	COVID-19 vaccine hesitancy and its drivers: An empirical study of the vaccine hesitant group in Malaysia. PLoS ONE, 2023, 18, e0282520.	2.5	0
161	An Optimal Vaccine Allocation Model Considering Vaccine Hesitancy and Efficacy Rates Among Populations. IEEE Access, 2023, 11, 27693-27701.	4.2	0
162	Vaccine hesitancy against COVID-19 vaccine over time in Nigeria. Vaccine, 2023, 41, 2749-2753.	3.8	4
163	A Novel Approach to Obtain Vaccine Effectiveness Continuous Profiles. Example Case: COVID-19 in Elderly Mexicans. Vaccines, 2023, 11, 719.	4.4	1
164	Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing. Clinical Chemistry and Laboratory Medicine, 2023, 61, 1670-1675.	2.3	3
165	Durability of Bivalent Boosters against Omicron Subvariants. New England Journal of Medicine, 2023, 388, 1818-1820.	27.0	46
166	The ambiguous future of the COVIDâ€19 pandemic in the presence of a vaccine. Health Science Reports, 2023, 6, .	1.5	1
167	External validation of unsupervised COVID-19 clinical phenotypes and their prognostic impact. Annals of Medicine, 2023, 55, .	3.8	1
168	SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. Vaccines, 2023, 11, 849.	4.4	12
169	Clinical Characteristics and Outcomes among Vaccinated and Unvaccinated Patients with Cardiovascular Disease Who Were Hospitalized for COVID-19 in Brazil: Retrospective Cohort. Vaccines, 2023, 11, 861.	4.4	1
172	Targeting the hallmarks of aging to improve influenza vaccine responses in older adults. Immunity and Ageing, 2023, 20, .	4.2	3
173	A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection. JCI Insight, 2023, 8 , .	5.0	2
174	Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort study. Vaccine, 2023, 41, 4274-4279.	3.8	0
175	The Art of Stem Cell-Based Therapy. Advances in Experimental Medicine and Biology, 2023, , 1-12.	1.6	0
176	SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	1
177	[Case Report] Supplementation with Vitamin D, Zinc, and Quercetin to Treat COVID-19: A Case Report. Qeios, 0, , .	0.0	0
178	Managing Outpatient Diabetes in Persons with COVID-19 and Diabetes. Contemporary Endocrinology, 2023, , 137-155.	0.1	0

#	Article	IF	CITATIONS
179	Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study. Lancet Infectious Diseases, The, 2023, 23, 1257-1265.	9.1	9
181	Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations. Vaccines, 2023, 11, 906.	4.4	5
182	Learning Topical Structured Interfaces from Medical Research Literature. , 2023, , .		0
183	Evaluation of Antibody Response and Adverse Effects following Heterologous COVID-19 Vaccine Booster with mRNA Vaccine among Healthcare Workers in Indonesia. Vaccines, 2023, 11, 1160.	4.4	2
184	Homologous or heterologous COVID-19 vaccine schemes: comparison of immune responses and side effects. Diagnostic Microbiology and Infectious Disease, 2023, 107, 116017.	1.8	0
185	Contribution of vaccinations to reducing socioeconomic disparities in COVID-19 deaths across U.S.Âcounties. Annals of Epidemiology, 2023, 86, 65-71.e3.	1.9	0
186	Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters. Nature Communications, 2023, 14, .	12.8	6
187	COVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients. Biomedicines, 2023, 11, 2055.	3.2	2
188	Proteinâ€Based Face Mask with High SARSâ€CoVâ€2 Neutralization Ability and Breathability. Advanced Materials Technologies, 0, , .	5.8	0
189	Long-term spatiotemporal analysis of the climate related impact on the transmission rate of COVID-19 Environmental Research, 2023, 236, 116741.	7.5	1
190	Association Between COVID-19 Vaccination and Mortality after Major Operations. Annals of Surgery, 0, , .	4.2	1
191	Pandemics and flexible lockdowns: In praise of agent-based modeling. European Journal for Philosophy of Science, 2023, 13, .	1.1	0
192	DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study. Vaccine, 2023, 41, 5525-5534.	3.8	0
193	Introduction to COVID-19., 2023, , 33-52.		0
194	Antibody response following the fourth SARSâ€CoVâ€2 vaccine dose during the Omicron wave in Brazil. Journal of Medical Virology, 2023, 95, .	5.0	0
195	Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel. Epidemiologia, 2023, 4, 309-321.	2.2	0
196	Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection. Nature Immunology, 2023, 24, 1711-1724.	14.5	17
197	A proportional incidence rate model for aggregated data to study the vaccine effectiveness against COVIDâ€19 hospital and ICU admissions. Biometrics, 0, , .	1.4	0

#	Article	IF	CITATIONS
198	Association of seizure with COVIDâ€19 vaccines in persons with epilepsy: A systematic review and metaâ€analysis. Journal of Medical Virology, 2023, 95, .	5.0	1
199	The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic. Frontiers in Medicine, 0 , 10 , .	2.6	0
200	SARS-CoV-2 variants of concern in children and adolescents with COVID-19: a systematic review. BMJ Open, 2023, 13, e072280.	1.9	0
201	Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVIDâ€19 vaccine Ad26.COV2.S in humans. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 1485-1498.	2.5	0
202	Post-acute sequelae of COVID-19 and longitudinal antibody levels in a community-based cohort. PLoS ONE, 2023, 18, e0291259.	2.5	1
203	Waning protection after vaccination and prior infection against COVID-19-related mortality over 18Âmonths. Clinical Microbiology and Infection, 2023, 29, 1573-1580.	6.0	2
204	Analysis of COVID-19 Case Demographics and Disease Outcomes in Gary, Indiana. International Journal of Environmental Research and Public Health, 2023, 20, 6729.	2.6	0
205	Application of a life table approach to assess duration of BNT162b2 vaccine-derived immunity by age using COVID-19 case surveillance data during the Omicron variant period. PLoS ONE, 2023, 18, e0291678.	2.5	0
207	Airway surveillance and lung viral control by memory T cells induced by COVID-19 mRNA vaccine. JCI Insight, 0, , .	5.0	0
208	Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study. The Lancet Regional Health - Western Pacific, 2023, 40, 100928.	2.9	5
209	Determinants of compliance to influenza and COVID-19 vaccination in a cohort of solid organ transplant patients in Puglia, Southern Italy (2017–2022). Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	1
210	Using the power of innate immunoprofiling to understand vaccine design, infection, and immunity. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	1
211	Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. The Cochrane Library, 2023, 2023, .	2.8	0
212	Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection. PLoS Pathogens, 2023, 19, e1011772.	4.7	0
213	Cardiovascular imaging in COVID-19: insights into features and complications., 0,, 59-71.		0
214	Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022–May 2023. Vaccine, 2023, , .	3.8	2
216	The Impact of Vaccination against SARS-CoV-2 on Health Outcomes and Hospital Visits after Omicron Infection in Children and Adolescents Aged 5–18 Years: A Danish Nation-Wide Cohort Study. Vaccines, 2023, 11, 1766.	4.4	0
217	Eleven-month SARS-CoV-2 binding antibody decay, and associated factors, among mRNA vaccinees: implications for booster vaccination. Access Microbiology, 2023, 5, .	0.5	1

#	Article	IF	CITATIONS
219	Effectiveness of the BNT162b2 vaccine in preventing morbidity and mortality associated with COVID-19 in children aged 5 to 11 years: A systematic review and meta-analysis. PLOS Global Public Health, 2023, 3, e0002676.	1.6	0
220	Seasonality of COVID-19 incidence in the United States. Frontiers in Public Health, 0, 11 , .	2.7	1
221	Modeling impact of vaccination on COVID-19 dynamics in St. Louis. Journal of Biological Dynamics, 2023, 17, .	1.7	0
222	Glucose control during breakthrough SARS-CoV-2 infections in vaccinated patients with type 1 diabetes. Diabetes Research and Clinical Practice, 2024, 207, 111044.	2.8	0
223	Quantitative microfluidic assay to measure neutralizing and total antibodies for SARS-CoV-2. Sensors and Actuators B: Chemical, 2024, 403, 135093.	7.8	0
225	Long-Term Analyses of SARS-CoV-2 Humoral and T Cell Responses and Breakthrough SARS-CoV-2 Infections after Two Doses of BNT162b2 Followed by mRNA-1273 and Bivalent Omicron-Adapted BNT162b2 Vaccines: A Prospective Study over 2 Years in Non-Immunocompromised Individuals. Vaccines, 2023. 11. 1835.	4.4	1
226	Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong. Emerging Infectious Diseases, 2024, 30, .	4.3	0
227	Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence. Microorganisms, 2024, 12, 89.	3.6	0
228	Magnitude and Durability of the Antibody Response to mRNA-Based Vaccination Among SARS-CoV-2 Seronegative and Seropositive Health Care Personnel. Open Forum Infectious Diseases, 2024, 11, .	0.9	0
229	Case Report: Acquired hemophilia A following COVID-19 vaccine. F1000Research, 0, 13, 65.	1.6	0
230	Mathematical Optimization Strategy for Effectiveness Profile Estimation in Two-Dose Vaccines and Its Use in Designing Improved Vaccination Strategies Focused on Pandemic Containment. Vaccines, 2024, 12, 81.	4.4	0
231	Exploring the Barriers and Facilitators of Mask-Wearing Behavior During the COVID-19 Pandemic in Taiwan, the United States, the Netherlands, and Haiti: A Qualitative Study. Disaster Medicine and Public Health Preparedness, 2024, 18, .	1.3	0
232	Estimate Time-To-Infection (TTI) Vaccination Effect When TTI for Unvaccinated Group is Unknown. Statistics in Biosciences, 0, , .	1.2	0
233	Immune Epitopes of SARS-CoV-2 Spike Protein and Considerations for Universal Vaccine Development. ImmunoHorizons, 2024, 8, 214-226.	1.8	0
234	Waning effectiveness of mRNA COVID-19 vaccines against inpatient and emergency department encounters. PLoS ONE, 2024, 19, e0300198.	2.5	0
235	Barriers to COVID-19 Vaccination in a Troop of Fleet Antiterrorism Security Team Marines: Observational Study. JMIR Formative Research, 0, 8, e50181.	1.4	0
236	Vaccination strategies impact the probability of outbreak extinction: A case study of COVID-19 transmission. Heliyon, 2024, 10, e28042.	3.2	0
237	Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework. Infectious Diseases and Therapy, 2024, 13, 779-811.	4.0	0

#	Article	IF	CITATIONS
238	Clinical and immunologic features of co-infection in COVID-19 patients, along with potential traditional Chinese medicine treatments. Frontiers in Immunology, 0, 15, .	4.8	0